Heron Therapeutics Future Growth
Future criteria checks 4/6
Heron Therapeutics is forecast to grow earnings and revenue by 70.7% and 17% per annum respectively while EPS is expected to grow by 70% per annum.
Key information
70.7%
Earnings growth rate
70.0%
EPS growth rate
| Biotechs earnings growth | 24.4% |
| Revenue growth rate | 17.0% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 08 May 2024 |
Recent future growth updates
Recent updates
Heron Therapeutics: Zynrelef Potentially Eases Shareholder Pain
Apr 16Here's What Analysts Are Forecasting For Heron Therapeutics, Inc. (NASDAQ:HRTX) After Its Full-Year Results
Mar 15
Heron Therapeutics, Inc. (NASDAQ:HRTX) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Feb 15Heron Therapeutics, Inc. (NASDAQ:HRTX) Held Back By Insufficient Growth Even After Shares Climb 27%
Dec 22Heron wins FDA nod for post-operative agent to address nausea and vomiting
Sep 16Is Heron Therapeutics (NASDAQ:HRTX) A Risky Investment?
Aug 10Heron Therapeutics Q2 2022 Earnings Preview
Aug 08Heron Therapeutics proposes 34% cut in workforce as part of cost reduction plan
Jun 30Heron Therapeutics: Cash Is A Problem Again
Mar 31Heron Therapeutics: Changing Strategy After Disappointing Earnings
Mar 03Health Check: How Prudently Does Heron Therapeutics (NASDAQ:HRTX) Use Debt?
Jan 19Heron Therapeutics: Looking For Signs Of The Bottom
Oct 07Is Heron Therapeutics (NASDAQ:HRTX) Using Too Much Debt?
Oct 03Need To Know: Analysts Just Made A Substantial Cut To Their Heron Therapeutics, Inc. (NASDAQ:HRTX) Estimates
Aug 11Shareholders May Be A Bit More Conservative With Heron Therapeutics, Inc.'s (NASDAQ:HRTX) CEO Compensation For Now
Jun 11Heron Therapeutics files for 12.4M common stock offering from shareholder
May 28Is Heron Therapeutics (NASDAQ:HRTX) A Risky Investment?
May 19Heron Therapeutics EPS misses by $0.03, misses on revenue
May 10Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Shift From Loss To Profit
Mar 10Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 217 | 40 | 24 | 32 | 3 |
| 12/31/2025 | 178 | 1 | -19 | -3 | 4 |
| 12/31/2024 | 148 | -14 | -33 | -30 | 4 |
| 3/31/2024 | 132 | -81 | -45 | -43 | N/A |
| 12/31/2023 | 127 | -111 | -60 | -59 | N/A |
| 9/30/2023 | 123 | -120 | -100 | -99 | N/A |
| 6/30/2023 | 118 | -137 | -128 | -127 | N/A |
| 3/31/2023 | 114 | -151 | -129 | -128 | N/A |
| 12/31/2022 | 108 | -182 | -149 | -147 | N/A |
| 9/30/2022 | 98 | -217 | -156 | -155 | N/A |
| 6/30/2022 | 95 | -227 | -174 | -171 | N/A |
| 3/31/2022 | 90 | -232 | -209 | -205 | N/A |
| 12/31/2021 | 86 | -221 | -206 | -203 | N/A |
| 9/30/2021 | 86 | -228 | -216 | -211 | N/A |
| 6/30/2021 | 83 | -234 | -204 | -200 | N/A |
| 3/31/2021 | 83 | -228 | -198 | -194 | N/A |
| 12/31/2020 | 89 | -227 | -192 | -185 | N/A |
| 9/30/2020 | 103 | -223 | -167 | -159 | N/A |
| 6/30/2020 | 126 | -198 | -149 | -143 | N/A |
| 3/31/2020 | 140 | -193 | -116 | -108 | N/A |
| 12/31/2019 | 146 | -205 | -132 | -125 | N/A |
| 9/30/2019 | 140 | -196 | -138 | -131 | N/A |
| 6/30/2019 | 117 | -201 | -153 | -141 | N/A |
| 3/31/2019 | 98 | -190 | -190 | -179 | N/A |
| 12/31/2018 | 77 | -179 | -201 | -192 | N/A |
| 9/30/2018 | 59 | -192 | -212 | -205 | N/A |
| 6/30/2018 | 47 | -195 | -213 | -210 | N/A |
| 3/31/2018 | 39 | -199 | -184 | -181 | N/A |
| 12/31/2017 | 31 | -197 | N/A | -170 | N/A |
| 9/30/2017 | 22 | -183 | N/A | -162 | N/A |
| 6/30/2017 | 13 | -190 | N/A | -157 | N/A |
| 3/31/2017 | 5 | -190 | N/A | -152 | N/A |
| 12/31/2016 | 1 | -173 | N/A | -134 | N/A |
| 9/30/2016 | N/A | -156 | N/A | -119 | N/A |
| 6/30/2016 | N/A | -131 | N/A | -102 | N/A |
| 3/31/2016 | N/A | -110 | N/A | -91 | N/A |
| 12/31/2015 | N/A | -98 | N/A | -79 | N/A |
| 9/30/2015 | N/A | -87 | N/A | -68 | N/A |
| 6/30/2015 | N/A | -83 | N/A | -68 | N/A |
| 3/31/2015 | N/A | -79 | N/A | -64 | N/A |
| 12/31/2014 | N/A | -76 | N/A | -60 | N/A |
| 9/30/2014 | N/A | -70 | N/A | -57 | N/A |
| 6/30/2014 | N/A | -63 | N/A | -50 | N/A |
| 3/31/2014 | N/A | -60 | N/A | -49 | N/A |
| 12/31/2013 | N/A | -55 | N/A | -41 | N/A |
| 9/30/2013 | N/A | -50 | N/A | -37 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HRTX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.4%).
Earnings vs Market: HRTX is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: HRTX is expected to become profitable in the next 3 years.
Revenue vs Market: HRTX's revenue (17% per year) is forecast to grow faster than the US market (8.3% per year).
High Growth Revenue: HRTX's revenue (17% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if HRTX's Return on Equity is forecast to be high in 3 years time